29/04/2016 19:36:12 1-888-992-3836 (toll free) Free Membership Login

Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
04/29/20163:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results Conference Call and Webcast Scheduled For Thursday, May 5, 2016 PR Newswire SAN DIEGO, April 29, 2016 SAN DIEGO, April 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will... More...>>
03/09/20161:00PMPRNUSNeurocrine Biosciences to Present at the Barclays Global Healthcare Conference
Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast will be on March 15, 2016 PR Newswire SAN DIEGO, March 9, 2016 SAN DIEGO, March 9, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences... More...>>
03/02/20166:30PMPRNUSNeurocrine Biosciences to Present at the Cowen and Company 36th Annual Health Care Conference
Neurocrine Biosciences to Present at the Cowen and Company 36th Annual Health Care Conference Live Audio Webcast will be on March 9, 2016 PR Newswire SAN DIEGO, March 2, 2016 SAN DIEGO, March 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
03/02/20168:30AMPRNUSNeurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine (NBI-98854) at the 68th Annual ...
Neurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine (NBI-98854) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver April 2016 Kinect 3 Clinical Study Data Accepted for Plenary Session Data From all Three Kinect Clinical Studies will be Presented PR Newswire... More...>>
02/11/20164:01PMPRNUSNeurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016
Neurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016 Valbenazine New Drug Application to be filed for Tardive Dyskinesia this Year Second Elagolix Phase III Study in Endometriosis is Successful Two Phase III Studies of Elagolix in Uterine Fibroids Underway Two Phase II Studies of Valbenazine... More...>>
02/08/20163:30PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2015 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2015 Results Conference Call and Webcast Scheduled For Thursday, February 11, 2016 PR Newswire SAN DIEGO, Feb. 8, 2016 SAN DIEGO, Feb. 8, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that... More...>>
02/03/20161:00PMPRNUSNeurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference Live Audio Webcast will be on February 10, 2016 PR Newswire SAN DIEGO, Feb. 3, 2016 SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO... More...>>
02/02/20168:30AMPRNUSNeurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with To...
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome Six-Week T-Force GREEN Study to Assess the Safety, Tolerability and Efficacy of Valbenazine in 90 Pediatric Subjects PR Newswire SAN DIEGO, Feb. 2, 2016 SAN DIEGO, Feb. 2, 2016 /PRNewswire/... More...>>
01/28/20166:55AMPRNUSAbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids - The Elagolix Phase 3 uterine fibroid clinical development program includes two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study. - Primary endpoint... More...>>
01/04/20162:00PMPRNUSNeurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 11, 2016 PR Newswire SAN DIEGO, Jan. 4, 2016 SAN DIEGO, Jan. 4, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
12/16/20154:05PMPRNUSNeurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children...
Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome Once-Daily Valbenazine was Safe and Well Tolerated with a 31% Reduction from Baseline in Tourette Symptoms after Two Weeks of Treatment Phase II Study in Children and Adolescents... More...>>
11/25/20151:00PMPRNUSNeurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference Live Audio Webcast will be on December 2, 2015 PR Newswire SAN DIEGO, Nov. 25, 2015 SAN DIEGO, Nov. 25, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/11/20152:10PMPRNUSNeurocrine Biosciences to Present at the Jefferies Autumn 2015 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies Autumn 2015 Global Healthcare Conference Live Audio Webcast will be on November 18, 2015 PR Newswire SAN DIEGO, Nov. 11, 2015 SAN DIEGO, Nov. 11, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/04/20153:30PMPRNUSNeurocrine Biosciences to Present at Credit Suisse's 24th Annual Healthcare Conference
Neurocrine Biosciences to Present at Credit Suisse's 24th Annual Healthcare Conference Live Audio Webcast will be on November 11, 2015 PR Newswire SAN DIEGO, Nov. 4, 2015 SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/04/20158:00AMPRNUSNeurocrine Biosciences Announces Expansion of its Clinical Pipeline
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline New Molecular Entity for Essential Tremor Enters Phase I Clinical Investigation PR Newswire SAN DIEGO, Nov. 4, 2015 SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and... More...>>
10/29/20154:01PMPRNUSNeurocrine Biosciences Reports Third Quarter 2015 Results
Neurocrine Biosciences Reports Third Quarter 2015 Results NBI-98854 Positive in Phase III Study in Tardive Dyskinesia, NDA filing in 2016 Elagolix Phase IIb Study in Uterine Fibroids is Positive, Moving into Phase III Development PR Newswire SAN DIEGO, Oct. 29, 2015 SAN DIEGO, Oct. 29, 2015 /PRNewswire/ -- Neurocrine... More...>>
10/22/20151:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results Conference Call and Webcast Scheduled For Thursday, October 29, 2015 PR Newswire SAN DIEGO, Oct. 22, 2015 SAN DIEGO, Oct. 22, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company... More...>>
10/20/20158:30AMPRNUSNeurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome Eight Week Study to Assess the Safety, Tolerability and Efficacy of Valbenazine in 90 Adult Subjects PR Newswire SAN DIEGO, Oct. 20, 2015 SAN DIEGO, Oct. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences... More...>>
10/08/20156:30AMPRNUSNeurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia Study Meets Primary Endpoint, Submission of New Drug Application Planned for 2016 Company to Host Conference Call and Webcast Thursday, October 8th at 8:00 AM EDT/ 5:00 AM PDT PR Newswire SAN DIEGO, Oct. 8, 2015 SAN DIEGO... More...>>
09/30/20154:30PMPRNUSNeurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors PR Newswire SAN DIEGO, Sept. 30, 2015 SAN DIEGO, Sept. 30, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has appointed George J. Morrow to its Board of Directors. Mr. Morrow has over... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20160429 23:36:14